New hope for kids with leukemia: Dual-Target therapy trial
NCT ID NCT06533748
Summary
This trial is testing whether adding two targeted immunotherapies, inotuzumab and blinatumomab, to standard chemotherapy can better control leukemia in children and young adults. It aims to see if this combination helps more patients achieve deep remission with minimal detectable cancer after initial treatment. The study will enroll 128 participants aged 1-18 with newly diagnosed high-risk B-cell acute lymphoblastic leukemia or lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Saint Francis Children's Hospital
RECRUITINGTulsa, Oklahoma, 74136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.